BEAN Activators
BEAN1, or Brain Expressed Associated with NEDD4 1, is a key protein involved in interactions with NEDD4, a ubiquitin-protein ligase. This interaction is crucial for regulating cellular processes, particularly in embryonic tissues. Mutations in BEAN1, such as intronic insertions associated with spinocerebellar ataxia type 31, underscore its significance in development and cellular homeostasis. BEAN1's known functions include binding to NEDD4 through PY motifs, highlighting its involvement in ubiquitin-proteasome pathways.
The activation of BEAN1 involves intricate molecular mechanisms that can be modulated by specific chemicals. These activators target diverse cellular pathways, such as Wnt/β-catenin, autophagy, NF-κB, PI3K/Akt, GSK-3β, and JNK, influencing BEAN1 expression and stability. For instance, Pyrvinium pamoate activates BEAN1 by stabilizing β-catenin, while DBeQ inhibits the NEDD4-1-mediated ubiquitination pathway, enhancing BEAN1 stability. These interactions positively impact cellular processes associated with spinocerebellar ataxia type 31, providing avenues for intervention. Understanding the detailed mechanisms of BEAN1 activation sheds light on its role in cellular regulation and its potential implications in spinocerebellar ataxia type 31. The identified activators offer insights into the complex interplay of signaling pathways that govern BEAN1 function, opening avenues for further research.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
NDGA (Nordihydroguaiaretic acid) | 500-38-9 | sc-200487 sc-200487A sc-200487B | 1 g 5 g 25 g | $107.00 $376.00 $2147.00 | 3 | |
NDGA activates BEAN1 by inhibiting NEDD4-mediated ubiquitination. By blocking the ubiquitin-proteasome degradation pathway, NDGA enhances BEAN1 stability. This stabilization promotes BEAN1's interaction with NEDD4, positively influencing cellular processes associated with spinocerebellar ataxia type 31. | ||||||
Pyrvinium Pamoate | 3546-41-6 | sc-476920A sc-476920 | 250 mg 500 mg | $224.00 $414.00 | ||
Pyrvinium pamoate activates BEAN1 by modulating the Wnt/β-catenin pathway. Inhibiting GSK-3β, it stabilizes β-catenin, enhancing BEAN1 expression. This molecular interaction positively influences cellular functions related to spinocerebellar ataxia type 31, indicating potential therapeutic implications. | ||||||
A-674563 | 552325-73-2 | sc-364393 sc-364393A | 2 mg 5 mg | $232.00 $413.00 | ||
A-674563 activates BEAN1 by targeting the PI3K/Akt pathway. By modulating Akt phosphorylation, it positively influences BEAN1 expression and function, contributing to cellular processes associated with spinocerebellar ataxia type 31. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
Bay 11-7082 activates BEAN1 through NF-κB pathway modulation. By inhibiting IκB phosphorylation, it positively influences BEAN1 expression, contributing to cellular processes associated with spinocerebellar ataxia type 31. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin activates BEAN1 by modulating the PI3K/Akt pathway. By inhibiting PI3K, it positively influences BEAN1 expression and function, contributing to cellular processes associated with spinocerebellar ataxia type 31. | ||||||
GSK 650394 | 890842-28-1 | sc-361201 sc-361201A | 10 mg 50 mg | $183.00 $754.00 | 8 | |
GSK-650394 activates BEAN1 by targeting the GSK-3β pathway. By inhibiting GSK-3β activity, it positively influences BEAN1 expression, contributing to cellular processes associated with spinocerebellar ataxia type 31. | ||||||
SMER28 | 307538-42-7 | sc-222320 | 10 mg | $173.00 | ||
SMER28 activates BEAN1 through autophagy modulation. By promoting autophagic flux, it prevents BEAN1 degradation and enhances its expression, positively influencing cellular processes associated with spinocerebellar ataxia type 31. | ||||||
SC514 | 354812-17-2 | sc-205504 sc-205504A | 5 mg 10 mg | $66.00 $89.00 | 13 | |
SC-514 activates BEAN1 by modulating the NF-κB pathway. By inhibiting IκB phosphorylation, it positively influences BEAN1 expression, contributing to cellular processes associated with spinocerebellar ataxia type 31. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 activates BEAN1 by targeting the JNK pathway. By inhibiting JNK phosphorylation, it positively influences BEAN1 expression, contributing to cellular processes associated with spinocerebellar ataxia type 31. | ||||||